The globally active CHEPLAPHARM Group, headquartered in Greifswald, has received the approval from the European Medicines Agency (EMA) for a new third-party manufacturing site for Zyprexa® tablets. This authorisation provides the basis for CHEPLAPHARM to supply the European markets via its own outsourced supply chain, marking a major milestone in ensuring global product availability of Zyprexa® tablets. The Greifswald-based company is collaborating with the German pharmaceutical company Fidelio Healthcare on the manufacture of Zyprexa® tablets and on the packaging of Zyprexa® Zydis ODT.
CHEPLAPHARM, the global market leader in acquiring established original products from research-based pharmaceutical companies, acquired the worldwide marketing rights (excluding South Korea) for Zyprexa® from Eli Lilly and Company in 2023. CHEPLAPHARM is now collaborating with Fidelio Healthcare on the manufacture of Zyprexa® tablets and on the packaging of Zyprexa® Zydis ODT, thereby transferring the production of the product from Eli Lily and Company to its own outsourced supply chain. The first products of this new collaboration have already been delivered to CHEPLAPHARM’s distribution and partner network.
“With the approval from the EMA we are strengthening the resilience of the supply chain for the oral formulations of our core product Zyprexa® and thereby ensuring product availability for patients and prescribers, particularly in Europe from now on. It also sends a strong signal to our investors that our transformation programme – optimizing our end-to-end processes – is taking effect. This success is the result of tremendous project management efforts within our company,” says Edeltraud Lafer, Co-CEO of CHEPLAPHARM.
Artem Gevorkyan, Senior Vice President of Corporate Development at CHEPLAPHARM, comments: “The speed and success of this critical milestone are a direct result of our new approach to post-acquisition integration. In April 2025, we established the Integration Management Office (IMO) to drive a fundamental organizational shift. By managing product implementation end-to-end our dedicated IMO function has significantly accelerated this project. This proven, cross-functional end-to-end model is now the standard for how we manage all future acquisitions at CHEPLAPHARM.”
Following approval in Europe, CHEPLAPHARM is strenuously pursuing approvals in further markets worldwide. The company anticipates securing approval in the US later in 2026, followed by other global markets, enabling CHEPLAPHARM to supply Zyprexa® tablets to patients worldwide from its base in Germany.
